Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

16.77 +1.05 (+6.71%)

Delayed Quote Updated: 12:27 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

September 04, 2024

From The Schall Law Firm

Via Business Wire

Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher ↗

September 03, 2024

Via Benzinga

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗

September 03, 2024

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...

Via Benzinga

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building ↗

September 03, 2024

The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.

Via Investor's Business Daily

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 03, 2024

Via Benzinga

Nasdaq Dips Over 2%; US Construction Spending Falls In July ↗

September 03, 2024

Via Benzinga

Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates ↗

September 03, 2024

Via Benzinga

Topics Stocks

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 03, 2024

Via Benzinga

Dyne Therapeutics Announces Key Leadership Appointments

September 03, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

September 03, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

August 29, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity? ↗

August 21, 2024

Find out the significance of the

Via Talk Markets

Topics Stocks

Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday? ↗

August 13, 2024

A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to...

Via Benzinga

Topics Economy

DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 ↗

August 12, 2024

DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 12, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗

July 14, 2024

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Via Benzinga

Chart Of The Day: Dyne Therapeutics - Deeply Discounted ↗

July 10, 2024

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United...

Via Talk Markets

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

June 24, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

June 13, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday ↗

June 12, 2024

Via Benzinga

Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React ↗

June 12, 2024

U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September.

Via Benzinga

Topics Economy

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

May 30, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

May 28, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

May 22, 2024

Via Benzinga

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

May 21, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

May 20, 2024

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why Is Dyne Therapeutics Stock Soaring On Monday? ↗

May 20, 2024

Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle...

Via Benzinga

Tech Surge Boosts Nasdaq To Record Highs ↗

May 20, 2024

The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks.

Via Talk Markets

Topics Stocks

Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again ↗

May 20, 2024

Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.